PriceTargets.com logo

Medpace - MEDP Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $380.00
  • Forecasted Upside: 17.63%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$323.04 As of 10/30/2024 03:53 PM ET
▼ -6.72 (-2.04%)

This chart shows the closing price for MEDP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Medpace Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MEDP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MEDP

Analyst Price Target is $380.00
▲ +17.63% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Medpace in the last 3 months. The average price target is $380.00, with a high forecast of $435.00 and a low forecast of $336.00. The average price target represents a 17.63% upside from the last price of $323.04.

This chart shows the closing price for MEDP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 11 contributing investment analysts is to hold stock in Medpace. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/23/2024Baird R WDowngradeStrong-Buy ➝ Hold
10/23/2024TD CowenLower TargetBuy ➝ Buy$413.00 ➝ $372.00
10/23/2024Robert W. BairdDowngradeOutperform ➝ Neutral$413.00 ➝ $349.00
10/22/2024William BlairReiterated RatingOutperform
10/14/2024Truist FinancialLower TargetHold ➝ Hold$415.00 ➝ $397.00
10/14/2024Redburn AtlanticInitiated CoverageBuy$404.00
9/27/2024UBS GroupDowngradeBuy ➝ Neutral$420.00 ➝ $350.00
9/25/2024Jefferies Financial GroupDowngradeBuy ➝ Hold$415.00 ➝ $345.00
9/20/2024Robert W. BairdLower TargetOutperform ➝ Outperform$430.00 ➝ $413.00
9/11/2024William BlairReiterated RatingOutperform
8/1/2024Truist FinancialInitiated CoverageHold$415.00
7/24/2024Robert W. BairdLower TargetOutperform ➝ Outperform$469.00 ➝ $430.00
7/24/2024Deutsche Bank AktiengesellschaftLower TargetHold ➝ Hold$395.00 ➝ $336.00
7/24/2024TD CowenLower TargetBuy ➝ Buy$452.00 ➝ $434.00
7/24/2024GuggenheimLower TargetBuy ➝ Buy$464.00 ➝ $432.00
7/23/2024William BlairReiterated RatingOutperform
7/8/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$456.00 ➝ $469.00
5/29/2024TD CowenInitiated CoverageBuy$452.00
5/28/2024MizuhoInitiated CoverageBuy$435.00
4/24/2024GuggenheimBoost TargetBuy ➝ Buy$453.00 ➝ $464.00
4/24/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$446.00 ➝ $454.00
4/23/2024Jefferies Financial GroupUpgradeHold ➝ Buy$340.00 ➝ $450.00
3/18/2024Deutsche Bank AktiengesellschaftInitiated CoverageHold$395.00
2/15/2024UBS GroupUpgradeNeutral ➝ Buy$282.00 ➝ $452.00
2/14/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$312.00 ➝ $408.00
1/17/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$302.00 ➝ $312.00
10/24/2023Robert W. BairdUpgradeNeutral ➝ Outperform$270.00 ➝ $289.00
9/8/2023Robert W. BairdBoost Target$240.00 ➝ $250.00
7/26/2023Robert W. BairdBoost Target$240.00 ➝ $260.00
7/26/2023UBS GroupBoost Target$215.00 ➝ $270.00
7/25/2023GuggenheimBoost TargetBuy$252.00 ➝ $273.00
5/8/202322nd Century GroupReiterated RatingUpgrade
5/8/2023GuggenheimUpgradeNeutral ➝ Buy$252.00
2/15/2023Robert W. BairdBoost TargetNeutral$226.00 ➝ $233.00
1/13/2023Robert W. BairdBoost Target$217.00 ➝ $226.00
10/27/2022UBS GroupUpgradeSell ➝ Neutral$142.00 ➝ $238.00
10/25/2022Robert W. BairdBoost TargetNeutral$145.00 ➝ $200.00
9/7/2022UBS GroupInitiated CoverageSell$142.00
5/23/2022GuggenheimInitiated CoverageNeutral
3/17/2022Robert W. BairdBoost Target$160.00 ➝ $175.00
2/16/2022Robert W. BairdLower Target$190.00 ➝ $160.00
7/27/2021Truist FinancialReiterated RatingBuy$167.90
7/27/2021Truist FinancialBoost TargetBuy$193.00 ➝ $200.00
7/20/2021Credit Suisse GroupBoost TargetOutperform$200.00 ➝ $205.00
3/17/2021Credit Suisse GroupBoost TargetOutperform$178.00 ➝ $181.00
2/17/2021Truist FinancialBoost Target$135.00 ➝ $180.00
2/16/2021Credit Suisse GroupBoost TargetOutperform$155.00 ➝ $178.00
10/2/2020Truist FinancialUpgradeHold ➝ Buy$124.00 ➝ $135.00
7/29/2020SunTrust BanksBoost TargetHold$95.00 ➝ $124.00
7/28/2020Credit Suisse GroupBoost TargetOutperform$92.00 ➝ $114.00
6/8/2020Robert W. BairdUpgradeUnderperform ➝ Neutral$83.00
5/13/2020Wolfe ResearchDowngradeOutperform ➝ Peer Perform$91.00
4/30/2020SunTrust BanksUpgradeSell ➝ Hold$54.00 ➝ $85.00
4/29/2020Credit Suisse GroupLower TargetOutperform$105.00 ➝ $92.00
4/20/2020Robert W. BairdDowngradeNeutral ➝ Underperform$77.00
4/6/2020SunTrust BanksBoost TargetSell$46.00 ➝ $54.00
3/23/2020Jefferies Financial GroupLower TargetHold$93.00 ➝ $75.00
3/17/2020SunTrust BanksDowngradeHold ➝ Sell$100.00 ➝ $46.00
2/26/2020SunTrust BanksSet Target$100.00
2/25/2020CSFBBoost TargetOutperform$91.00 ➝ $99.00
2/25/2020Credit Suisse GroupBoost TargetOutperform$91.00 ➝ $99.00
1/27/2020SunTrust BanksDowngradeBuy ➝ Hold$85.00 ➝ $87.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.57 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 23 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2024
  • 29 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/3/2024
  • 34 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2024
  • 19 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2024
  • 23 very positive mentions
  • 19 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2024
  • 15 very positive mentions
  • 24 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2024
  • 26 very positive mentions
  • 13 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 23 very positive mentions
  • 38 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
10/30/2024

Current Sentiment

  • 23 very positive mentions
  • 38 positive mentions
  • 6 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Medpace logo
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Read More

Today's Range

Now: $323.04
Low: $323.04
High: $331.99

50 Day Range

MA: $349.01
Low: $320.58
High: $395.71

52 Week Range

Now: $323.04
Low: $239.00
High: $459.77

Volume

138,593 shs

Average Volume

273,789 shs

Market Capitalization

$10.01 billion

P/E Ratio

28.29

Dividend Yield

N/A

Beta

1.35

Frequently Asked Questions

What sell-side analysts currently cover shares of Medpace?

The following Wall Street research analysts have issued stock ratings on Medpace in the last year: Baird R W, Deutsche Bank Aktiengesellschaft, Guggenheim, Jefferies Financial Group Inc., Mizuho, Redburn Atlantic, Robert W. Baird, StockNews.com, TD Cowen, Truist Financial Co., UBS Group AG, and William Blair.
View the latest analyst ratings for MEDP.

What is the current price target for Medpace?

9 Wall Street analysts have set twelve-month price targets for Medpace in the last year. Their average twelve-month price target is $380.00, suggesting a possible upside of 17.1%. Mizuho has the highest price target set, predicting MEDP will reach $435.00 in the next twelve months. Deutsche Bank Aktiengesellschaft has the lowest price target set, forecasting a price of $336.00 for Medpace in the next year.
View the latest price targets for MEDP.

What is the current consensus analyst rating for Medpace?

Medpace currently has 6 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MEDP, but not buy more shares or sell existing shares.
View the latest ratings for MEDP.

What other companies compete with Medpace?

Other companies that are similar to Medpace include PRA Health Sciences, Exelixis, Syneos Health, Laboratory Co. of America and National Research. Learn More about companies similar to Medpace.

How do I contact Medpace's investor relations team?

Medpace's physical mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company's listed phone number is (513) 579-9911 and its investor relations email address is [email protected]. The official website for Medpace is www.medpace.com. Learn More about contacing Medpace investor relations.